title: Experiences with immunomodulant agents in HIV infections.
abstract: Drug addicts with persistent generalized lymphadenopathy displayed the following immunological abnormalities: an inverted OKT4/OKT8 ratio, a depressed in vitro blastogenetic response to phytohemagglutinin and pokeweed mitogen (PWM), a reduced ability of PMNL to phagocytose and kill Candida albicans spores and to migrate in presence of a chemotactic factor. Thymopentin treatment (50 mg s.c. 3 times/week for 3 weeks and repeated after 3 months at 50 mg s.c. once a week for 3 months) improved OKT4+ lymphocytes (p less than 0.05) and the blastogenesis to PWM (p less than 0.01); moreover, at the end of the first cycle, the chemotaxis of neutrophils was increased to normal values.
mesh_terms: D000386:AIDS-Related Complex / Q000276:immunology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002633:Chemotaxis / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D010587:Phagocytosis / Q000187:drug effects; D019966:Substance-Related Disorders / Q000150:complications; D016305:Thymopentin; D013946:Thymopoietins / Q000494:pharmacology / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin